In fact, from a commercial point of view the pharmaceutical industry has no interest in committing to research costs, given the low number of people affected by these rare diseases.
Fra et rent økonomisk synspunkt har lægemiddelindustrien nemlig på grund af det lave antal borgere, der rammes af disse sjældne sygdomme, ingen interesse i at påtage sig forskningsudgifter.